Global Longlife Hospital And Research Ltd vs Lotus Eye Hospital Institute Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Global Longlife Hospital and Research Ltd is ₹ 12.82 as of 30 Oct 15:30 . The P/E Ratio of Global Longlife Hospital and Research Ltd changed from 25.7 on March 2023 to 0 on March 2026 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Lotus Eye Hospital & Institute Ltd changed from 55.9 on March 2021 to 2533 on March 2026 . This represents a CAGR of 88.83% over 6 years The Market Cap of Global Longlife Hospital and Research Ltd changed from ₹ 47.02 crore on March 2023 to ₹ 14.34 crore on March 2026 . This represents a CAGR of -25.69% over 4 yearsThe Market Cap of Lotus Eye Hospital & Institute Ltd changed from ₹ 87.14 crore on March 2021 to ₹ 210.77 crore on March 2026 . This represents a CAGR of 15.86% over 6 years The revenue of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 17.27 crore as compare to the Mar '26 revenue of ₹ 14.09 crore. This represent the growth of 22.57% The ebitda of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 3.15 crore as compare to the Mar '26 ebitda of ₹ 0.95 crore. This represent the growth of 231.58% The net profit of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Lotus Eye Hospital & Institute Ltd changed from ₹ 0.62 crore to ₹ 0.61 crore over 9 quarters. This represents a CAGR of -0.72% The Dividend Payout of Global Longlife Hospital and Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Lotus Eye Hospital & Institute Ltd changed from 66.24 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 years .

About Global Longlife Hospital and Research Ltd

Global Longlife Hospital and Research Limited was originally incorporated as 'Global Longlife Hospital and Research Private Limited' on January 20, 2012 with Registrar of Companies, Gujarat.
Subsequently, Company was converted into a Public Limited Company and , name of the Company was changed to 'Global Longlife Hospital and Research Limited' vide fresh Certificate of Incorporation dated August 31, 2021. The Company had acquired 1339 sq.mt. area land in the prime locality of Ahmedabad for starting hospital in March 2012.
The Hospital started journey in 2015 & determined to build an institution in Ahmedabad.
Mr. Dhruv Jani had also joined the hospital business with his father in July 2015.
The majority Equity shares of the Company were taken over by the present Promoters by acquiring the Equity shares from the Doctors and investors in the year 2017.

About Lotus Eye Hospital & Institute Ltd

Lotus Eye Hospital & Institute Limited, a trust hospital, was originally incorporated as 'Kalaivani Health Centre Pvt.
Limited' on 14 March, 1997.
The name of the Company was changed to 'Lotus Eye Care Hospital Pvt.
Limited' on 23 January, 2006 and later on, the Company was converted into a Public Limited Company on October 16, 2007 and subsequently, the name was changed to Lotus Eye Hospital & Institute Limited on April 12, 2013. Founded in 1990 by renowned ophthalmic surgeon late Dr. S.K. Sundaramoorthy, the Company operates 9 Eye Care centers in Tamil Nadu and Kerala: 7 Centres in Tamil Nadu: Coimbatore (Peelamedu, RS puramand Saravanampatti), Salem , Tirupur Mettupalayam and Karur. 2 Centresin Kerala: Kochi and Mulanthuruthy. Lotus Eye Care Hospital is the state of art eye care hospital group functioning in South India with specialization in super-specialty service related to eye care.

FAQs for the comparison of Global Longlife Hospital and Research Ltd and Lotus Eye Hospital & Institute Ltd

Which company has a larger market capitalization, Global Longlife Hospital and Research Ltd or Lotus Eye Hospital & Institute Ltd?

Market cap of Global Longlife Hospital and Research Ltd is 13 Cr while Market cap of Lotus Eye Hospital & Institute Ltd is 221 Cr

What are the key factors driving the stock performance of Global Longlife Hospital and Research Ltd and Lotus Eye Hospital & Institute Ltd?

The stock performance of Global Longlife Hospital and Research Ltd and Lotus Eye Hospital & Institute Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Global Longlife Hospital and Research Ltd and Lotus Eye Hospital & Institute Ltd?

As of November 1, 2026, the Global Longlife Hospital and Research Ltd stock price is INR ₹12.82. On the other hand, Lotus Eye Hospital & Institute Ltd stock price is INR ₹106.5.

How do dividend payouts of Global Longlife Hospital and Research Ltd and Lotus Eye Hospital & Institute Ltd compare?

To compare the dividend payouts of Global Longlife Hospital and Research Ltd and Lotus Eye Hospital & Institute Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.